The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir -: Part I.: Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir

被引:29
作者
Périgaud, C
Gosselin, G
Girardet, JL
Korba, BE
Imbach, JL
机构
[1] Univ Montpellier 2, CNRS, UMR 5625, Chim Bioorgan Lab, F-34095 Montpellier 5, France
[2] Georgetown Univ, Div Mol Virol & Immunol, Rockville, MD 20852 USA
关键词
acyclovir; hepatitis B virus; nucleotide; prodrug; synergy;
D O I
10.1016/S0166-3542(98)00059-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The synthesis and in vitro anti-hepatitis B virus (HBV) activity of two mononucleoside phosphotriester derivatives of acyclovir incorporating S-acyl-2-thioethyl (SATE) groups are reported. In contrast to the parent nucleoside, the described phosphotriesters emerged as potent and selective inhibitors of HBV replication in HepG2.2.15 cells. This result can be attributed to the unique cellular metabolism of the SATE pronucleotides giving rise to the delivery to acyclovir 5'-monophosphate inside the infected cells. Moreover, the in vitro anti-HBV activities of one of these bis(SATE)phosphotriesters and of(-)-beta-L-2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC) were compared alone and in combination. Analysis of the combination data indicates that 3TC and the studied SATE pronucleotide of acyclovir exhibited strong synergistic interactions. The present study provides an example where the use of a pronucleotide approach extends the antiviral spectrum of a nucleoside analogue. Given the potency of SATE pronucleotides of acyclovir against HBV in HepG2.2.15 cells, further studies including animal experiments seem warranted to evaluate the potential of these compounds as anti-HBV agents. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:167 / 178
页数:12
相关论文
共 40 条
[1]   CONTROLLED CLINICAL-TRIAL OF ACYCLOVIR IN CHRONIC HEPATITIS-B VIRUS-INFECTION [J].
ALEXANDER, GJM ;
FAGAN, EA ;
HEGARTY, JE ;
YEO, J ;
EDDLESTON, ALWF ;
WILLIAMS, R .
JOURNAL OF MEDICAL VIROLOGY, 1987, 21 (01) :81-87
[2]   PRODRUGS OF ANALOGS OF NUCLEIC-ACID COMPONENTS [J].
ALEXANDER, P ;
HOLY, A .
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1994, 59 (10) :2127-2165
[3]  
Alvarez F, 1996, CLIN INVEST MED, V19, P381
[4]  
[Anonymous], CURRENT TOPICS MED C
[5]   INVITRO INHIBITION OF HEPATITIS-B VIRUS-REPLICATION BY 2',3'-DIDEOXYGUANOSINE, 2',3'-DIDEOXYINOSINE, AND 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE IN 2.2.15 (PR) CELLS [J].
AOKISEI, S ;
OBRIEN, MC ;
FORD, H ;
FUJII, H ;
GILBERT, DA ;
COONEY, DA ;
JOHNS, DG ;
BRODER, S ;
MITSUYA, H .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (05) :843-851
[6]   MAMMALIAN DEOXYRIBONUCLEOSIDE KINASES [J].
ARNER, ESJ ;
ERIKSSON, S .
PHARMACOLOGY & THERAPEUTICS, 1995, 67 (02) :155-186
[7]   MULTIPLE-DRUG EFFECT ANALYSIS WITH CONFIDENCE-INTERVAL [J].
BELENKII, MS ;
SCHINAZI, RF .
ANTIVIRAL RESEARCH, 1994, 25 (01) :1-11
[8]   FAILURE OF ACYCLOVIR TO ENHANCE THE ANTIVIRAL EFFECT OF ALPHA-LYMPHOBLASTOID INTERFERON ON HBE-SEROCONVERSION IN CHRONIC HEPATITIS-B - A MULTICENTER RANDOMIZED CONTROLLED TRIAL [J].
BERK, L ;
SCHALM, SW ;
DEMAN, RA ;
HEYTINK, RA ;
BERTHELOT, P ;
BRECHOT, C ;
BOBOC, B ;
DEGOS, F ;
MARCELLIN, P ;
BENHAMOU, JP ;
HESS, G ;
ROSSOL, S ;
ZUMBUSCHENFELDE, KHM ;
CHAMULEAU, RAFM ;
JANSEN, PLM ;
REESINK, HW ;
MEYER, B ;
BEGLINGER, C ;
STALDER, GA ;
DENOUDENMULLER, JW ;
DEJONG, M .
JOURNAL OF HEPATOLOGY, 1992, 14 (2-3) :305-309
[9]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[10]  
CHOU TC, 1991, SYNERGISM ANTAGONISM, P61